0
Abstract: Poster Presentations |

LOVASTATIN BUT NOT ERLOTINIB REDUCES THE PROLIFERATION OF IMMORTALIZED BRONCHIAL EPITHELIAL CELLS WITH K-RAS MUTATIONS FREE TO VIEW

Sridhar K. Prasad, MD*; Steven M. Dubinett, MD
Author and Funding Information

University of California, Los Angeles, Los Angeles, CA



Chest. 2006;130(4_MeetingAbstracts):233S-d-234S. doi:10.1378/chest.130.4_MeetingAbstracts.233S-d
Text Size: A A A
Published online

Abstract

PURPOSE: K-ras mutations appear to predict resistance to treatment of NSCLC with EGFR TKIs such as erlotinib. The mechanisms of K-ras mediated resistance is unknown, but K-ras potentially can be targeted by statin drugs. Our goals were to study the mechanisms of erlotinib resistance mediated by K-ras in immortalized cells, as well as the consequence of statin treatment.

METHODS: Human Immortalized Bronchial Epithelial Cells (HBEC) and HBEC with K-ras mutations (Dr. JD Minna, UT Southwestern) were plated for proliferation assays and PGE2 production following treatment with lovastatin, mevalonate, erlotinib and celecoxib. EGFR signaling was assessed by pulsing treated cells with EGF over 0-60 minutes and assaying for pERK and pAkt levels.

RESULTS: Erlotinib markedly reduced the proliferation and pERK signaling of HBEC cells; however, K-ras cells were resistant. Lovastatin reduced K-ras cellular proliferation, which was partially reversed by mevalonate addition. Compared to HBEC cells, K-ras cells had markedly elevated PGE2/COX-2 levels that increased following treatment with lovastatin. PGE2/COX-2 production was reversible by mevalonate. Compared to either agent alone, combination treatment with lovastatin and celecoxib had augmented anti-proliferative effect on K-ras cells. However, the combination of lovastatin and erlotinib did not have augmented anti-proliferation compared to lovastatin alone. Finally, lovastatin and celecoxib in combination, but not alone, reduced both constitutive and EGF induced pERK and pAkt signaling in K-ras cells.

CONCLUSION: K-ras mutant cells are resistant to erlotinib, an effect that may be due to persistent constitutive pERK signaling. K-ras mutants also demonstrated high PGE2/COX-2 levels, which increased following lovastatin treatment. Lovastatin reduced the proliferation of K-ras mutants, and in combination with celecoxib, had an augmented anti-proliferative effect. Furthermore, the combination of celecoxib and lovastatin reduced constitutive and EGF-induced pERK signaling.

CLINICAL IMPLICATIONS: Lovastatin may have a role in the chemoprevention and treatment of NSCLC, in combination with other targeted chemotherapies such as erlotinib and celecoxib.

DISCLOSURE: Sridhar Prasad, None.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543